We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




STI Molecular Test Delivers Rapid POC Results for Treatment Guidance

By LabMedica International staff writers
Posted on 24 Dec 2025

An affordable, rapid molecular diagnostic for sexually transmitted infections (STIs) has the potential to be globally relevant, particularly in resource-limited settings where rapid, point-of-care results can significantly impact both individual treatment and antibiotic stewardship. More...

Scout Health (Santa Clara, CA, USA) is finalizing the development of STI Scout, a rapid molecular test for detecting Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct) infections in under 30 minutes. The STI Scout test can use either first void urine or vaginal swabs, and future tests will be able to guide therapy for gonorrhea treatment based on antibiotic susceptibility. Designed for both point-of-care (POC) and over-the-counter (OTC) use, the test runs on the Scout Hub near-patient molecular platform, which enables earlier organism identification, resistance prediction, and better antimicrobial stewardship.

The Scout Hub test platform leverages a proprietary molecular chemistry that enables rapid detection of multiple pathogens in a single tube. This results in a test platform with orders-of-magnitude lower cost than commercially available clinical solutions while maintaining a sensitivity that can detect targets missed by rapid antigen tests. Because the system relies on minimal hardware and low-cost consumables, it can be manufactured and scaled efficiently. STI Scout uses the Scout Connect mobile app, which provides instructions, tracks results, and eventually will also allow patients to connect digitally to a healthcare provider.

Scout has been awarded additional funding from CARB-X to investigate a pilot in a low- or middle-income country, reflecting the platform's ability to extend high-quality molecular STI testing to resource and infrastructure-constrained settings. Expanding access to accurate molecular testing in settings where treatment is often empirical can support more appropriate therapy decisions and help reduce unnecessary antibiotic use.

"Cost is the number one barrier for adoption of rapid molecular testing in the US and abroad,” said Alex Jiao, PhD, CEO and Co-Founder of Scout. “COVID showed the limits of expensive, complex systems. Even with strong performance, their economics made sustained adoption impossible. Scout has focused on lowering cost through advances in chemistry and simplifying test design, enabling a platform that meets molecular performance requirements at a price point that supports a lasting, impactful solution."

Related Links:
Scout Health 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.